Articles related to CLINICAL TRIALS

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Semaglutide has been shown to reduce the risk of major kidney disease events and cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

The phase 3 trial of aficamten for symptomatic obstructive hypertrophic cardiomyopathy showed a significant improvement in peak oxygen uptake compared to placebo, with meaningful enhancements in patient-reported outcomes and clinical measures.

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.

In a recent clinical trial, thrombectomy combined with medical care was shown to significantly improve functional outcomes in patients with large acute strokes, reducing mortality rates to 36.1% compared to 55.5% in those receiving only medical care.